[1]张姝婷,李壮琪,刘 宝.药品价格国际比较的方法选择及可解释性研究[J].卫生经济研究,2026,43(05):44-50.
　ZHANG Shuting,LI Zhuangqi,LIU Bao.Method Selection and Interpretability of International Drug Price Comparisons[J].Journal Press of Health Economics Research,2026,43(05):44-50.
点击复制

药品价格国际比较的方法选择及可解释性研究

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年05期
页码:
44-50
栏目:
卫生服务价格
出版日期:
2026-04-24

文章信息/Info

Title:
Method Selection and Interpretability of International Drug Price Comparisons
作者:
张姝婷1; 李壮琪1; 刘 宝1
1.复旦大学公共卫生学院，国家卫生健康委员会卫生技术评估重点实验室，上海 200032
Author(s):
ZHANG Shuting;  LI Zhuangqi;  LIU Bao
School of Public Health, Fudan University, NHC Key Laboratory of Health Technology Assessment, Shanghai 200032, China
关键词:
药品价格; 国际比较; “中位价格比”方法
Keywords:
drug prices;  international comparison;  median price ratio method
分类号:
R19
文献标志码:
A
摘要:
药品价格水平直接关乎药品可负担性、公平性及公共政策的科学制定。世界卫生组织与国际健康行动组织推荐使用“中位价格比”方法进行药品价格的国际比较。该方法具有简便性与标准化优势，但在药品样本代表性、价格层级选择、汇率换算及比较基准等方面存在不确定性，可能影响比较结果的可解释性。因此，在基于药品价格国际比较制定监管决策时，应慎重选择比较方法，建议同时使用市场汇率和购买力平价方法进行交叉验证，避免数据处理偏倚。鉴于我国监管需求，应尽快开展参考国家篮子选择及相关国家价格监管政策研究，以高效开展药品价格国际比较并合理解读比较结果，进而支持监管决策。
Abstract:
The level of pharmaceutical prices is directly related to medicine affordability, equity, and the evidence-based formulation of public policies. The World Health Organization(WHO) and Health Action International(HAI) recommend the median price ratio method for international comparison of pharmaceutical prices. This method features simplicity and standardization, yet it entails uncertainties in terms of pharmaceutical sample representativeness, price tier selection, currency conversion and comparison benchmarks, which may undermine the interpretability of comparison outcomes.Therefore, when formulating regulatory decisions based on international pharmaceutical price comparisons, comparison methods should be selected with prudence. It is advisable to adopt cross-verification by simultaneously applying market exchange rates and purchasing power parity to mitigate biases in data processing. In view of China's regulatory demands, research on the selection of reference country baskets and relevant national price regulatory policies should be promptly advanced. Such efforts will facilitate efficient international pharmaceutical price comparison and rational interpretation of relevant findings, thereby providing solid evidence for regulatory decision-making.

参考文献/References:

[1] WHO, HAI. Measuring Medicine Prices, Availability, Affordability And Price Components: 2nd Edition[M]. Geneva: World Health Organization, 2016.
[2] Andersson F. Methodological aspects of international drug price comparisons[J]. Pharmaco Economics, 1993, 4(04): 247-256.
[3] Strengthening health services delivery: strengthening nursing and midwifery: report by the Secretariat[R]. 2025.
[4] Collecting Evidence on Medicine Prices & Availability[EB/OL]. [2025-09-27]. https://haiweb.org/what-we-do/price-availability-affordability/collecting-evidence-on-medicine-prices-availability/.
[5] Rida N A, Mohamed Ibrahim M I, Babar Z U D. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon[J]. BMC Health Services Research, 2019, 19: 1-14.
[6] Sooksriwong C, Hirunrassamee S, Suwattanapreeda S, et al. Monitoring the impact of regulatory measures on medicine pricing in Thailand: an observation over a 16-year span[J/OL]. Journal of Pharmaceutical Policy and Practice, 2025, 18(01): 2465801.
[7] Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis[J]. The Lancet, 2009, 373(9659): 240-249.
[8] Oldfield, Lachlan, Penm, et al. Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis - The Lancet Global Health[J]. The Lancet Global Health, 2025, 13(01): e50-e58.
[9] Cameron A, Bansal A, Dua T, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries[J]. Epilepsia, 2012, 53(06): 962-969.
[10] Wang H, Sun Q, Vitry A, et al. Availability, price, and affordability of selected essential medicines for chronic diseases in 11 countries of the Asia pacific region: a secondary analysis[J]. Asia-Pacific Journal of Public Health, 2017, 29(04): 268-277.
[11] Rathore A S, Gardner P J, Chhabra H, et al. Global outlook on affordability of biotherapeutic drugs[J]. Annals of the New York Academy of Sciences, 2024, 1537(01): 168-178.
[12] Oldfield L, Penm J, Moles R. Exploring access to essential medicines in the South Pacific: insights from a multi-country cross-sectional study[J/OL]. The Lancet Regional Health Western Pacific, 2025, 54: 101262.
[13] van Mourik M S, Cameron A, Ewen M, et al. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data[J/OL]. BMC Cardiovascular Disorders, 2010, 10: 25.
[14] Moye-Holz D, Vogler S. Comparison of prices and affordability of cancer medicines in 16 countries in Europe and Latin America[J]. Applied Health Economics and Health Policy, 2022, 20(01): 67-77.
[15] 姜明欢，王乐，王文娟，等.基于WHO/HAI标准化调查法对陕西省慢性病用药价格与供应情况的调查分析[J].中国药房，2013，24（28）：2598-2601.
[16] Xi X, Li W, Li J, et al. A survey of the availability, prices and affordability of essential medicines in Jiangsu Province, China[J/OL]. BMC Health Services Research, 2015, 15(01): 345.
[17] 张瑜，李歆.基于WHO/HAI标准调查方法的南京市基本药物可获得性及可负担性调查分析[J].中国药房，2015，26（30）：4188-4192.
[18] 王潇，曹建英，张金环，等.基于WHO/HAI标准化法的山东省50种药品价格及可获得性研究[J].中国药师，2021，24（10）:1877-1881.
[19] Dong Z, Tao Q, Sun G. Survey and analysis of the availability and affordability of essential drugs in Hefei based on WHO/HAI standard survey methods[J]. BMC Public Health, 2020, 20: 1-10.
[20] Gong S, Cai H, Ding Y, et al. The availability, price and affordability of antidiabetic drugs in Hubei Province, China[J]. Health Policy and Planning, 2018, 33(08): 937-947.
[21] Dong Z, Zhang S, Wu S, et al. Study on the accessibility and affordability of 50 drugs in Wuhan based on the WHO/HAI standardization method[J]. Frontiers in Public Health, 2023, 11: 1108007.
[22] Liu C, Zhang X, Liu C, et al. Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China[J/OL]. BMC Health Services Research, 2017, 17(01): 597-599.
[23] Wang L, Dai L, Liu H, et al. Availability, affordability and price components of insulin products in different-level hospital pharmacies: Evidence from two cross-sectional surveys in Nanjing, China[J/OL]. PLoS One, 2021, 16(08): e0255742.
[24] 王潇，杨世民，方宇，等.基于WHO/HAI标准化法的陕西省公立医院儿童基本药物可获得性及价格研究[J].中国药房，2014，25（08）：681-684.
[25] Chen Z, Li S, Choonara I, et al. Accessibility of essential medicines for children in Sichuan Province of China: a cross-sectional study[J]. Frontiers in Pharmacology, 2022, 13: 828152.
[26] Mu Y, Song K, Song Y. A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China[J/OL]. International Journal of Environmental Research and Public Health, 2022, 19(20): 13319.
[27] Sun Y, Qiang Y, Duan Y, et al. Impact of the National Drug Price Negotiation policy on the price, usage, and affordability of anticancer medicines in Shandong Province, China[J]. Frontiers in Public Health, 2025, 12: 1368718.
[28] WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2025[M]. Oslo: Norwegian Institute of Public Health, 2025.
[29] World Bank. Global Purchasing Power Parities and Real Expenditures: 2005 International Comparison Program[R]. Washington, DC: World Bank, 2008.
[30] WHO, HAI. Medicine Prices in Nigeria - Prices People Pay for Medicines[M]. Brazzaville: WHO Regional Office for Africa, 2004.

相似文献/References:

[1]周引德,傅鸿鹏.基层医疗机构药品配备使用情况分析[J].卫生经济研究,2016,(05):38.
[2]赵 静.药品价格改革问题研究[J].卫生经济研究,2016,(07):51.
[3]李银才.药品价格市场形成机制改革研究[J].卫生经济研究,2016,(07):55.
[4]黄泽华,潘 越,钭江苑,等.药物经济学在医保决策中的应用[J].卫生经济研究,2017,(03):37.
[5]胡善联.药品购销“两票制”政策的理论和实践[J].卫生经济研究,2017,(04):8.
[6]乔家骏,曾旖旎,傅鸿鹏.“两票制”对药企经济运行及药品价格的影响[J].卫生经济研究,2018,(10):61.
　QIAO Jia-jun,ZENG Yi-ni,FU Hong-peng.The Influence of “Two-vote System” on the Economic Operation of Pharmaceutical Companies and Drug Prices[J].Journal Press of Health Economics Research,2018,(05):61.
[7]吴 天.药品集中采购价格与药品费用控制研究[J].卫生经济研究,2018,(12):32.
　WU Tian.Research on Centralized Purchasing Price and Drug Cost Control of Medicines[J].Journal Press of Health Economics Research,2018,(05):32.
[8]殷 婷,汤少梁.基于消费者剩余理论的患者药品福利研究[J].卫生经济研究,2019,(02):13.
　YIN Ting,TANG Shao-liang.Research on Patient Drug Welfare Based on Consumer Surplus Theory[J].Journal Press of Health Economics Research,2019,(05):13.
[9]潘 静,王艳翚.区域差异化背景下我国23个省市药价水平比较分析[J].卫生经济研究,2019,(02):49.
　PAN Jing,WANG Yan-hui.Comparative Analysis of Drug Price Levels in 23 Provinces and Cities in China under the Background of Regional Differentiation[J].Journal Press of Health Economics Research,2019,(05):49.
[10]舒 茜,姚峥嵘,王艳翚,等.药品带量采购政策的利益相关者分析[J].卫生经济研究,2019,(08):8.
　SHU Qian,YAO Zheng-rong,WANG Yan-hui,et al.Stakeholder Analysis of Drug Consumption Policy[J].Journal Press of Health Economics Research,2019,(05):8.

更新日期/Last Update: 2026-04-24